FTC Forces Preliminary Settlement in Texas Anesthesia Market
Federal Trade Commission
On April 23, 2026, the Federal Trade Commission announced an agreement in principle to settle its 2023 antitrust case against U.S. Anesthesia Partners Inc. (USAP).
This settlement marks a critical inflection point in the FTC’s aggressive, post-Lina Khan crusade against private equity "roll-up" strategies in healthcare, an enforcement priority supercharged by the widespread collapse of independent physician practices following the pandemic.
The agency is moving to dismantle what it alleges was a decade-long corporate roll-up scheme by targeting a series of acquisitions that, individually, fell below the Hart-Scott-Rodino reporting thresholds but cumulatively resulted in massive market power.
The FTC claims USAP systematically acquired nearly every large anesthesia practice in Texas, creating a dominant single provider that inflated consumer healthcare costs by tens of millions of dollars annually.
This aggressive posture signals a clear warning to private equity firms that the FTC is willing to pursue novel legal theories to pierce the corporate veil and hold financial sponsors accountable for the anticompetitive behavior of their portfolio companies.
Now comes the enforcement reality. The exact terms of the agreement remain strictly confidential. This temporary secrecy facilitates USAP's ongoing negotiations to execute the mandated structural settlement.
The likely outcome will involve forced divestitures of specific regional practices, unwinding years of integration and instantly creating a volatile secondary market for anesthesia assets in Texas.
Commission staff recently secured a 2-0 vote authorizing them to file for a stay in the litigation, halting legal proceedings while USAP implements the required market relief for Texas consumers.
"If USAP fails fully to execute the settlement, the FTC will return to district court to litigate these unlawful acquisitions."
The legal mechanics hinge entirely on judicial approval. Joint motions for a stay, along with any stipulated final order resolving the case, require a formal Commission vote and a final sign-off from the District Court.
The scope of the action is tightly contained, targeting only the consolidation of anesthesia services across the state of Texas.
However, this containment is a strategic mirage. Private equity sponsors operating in dermatology, gastroenterology, and emergency medicine across the country are already re-evaluating their risk profiles, anticipating that the FTC will copy-paste this enforcement blueprint into other heavily consolidated medical sectors.
No broader medical sectors or alternative geographic markets are named, and the release outlines no explicit safe harbors or exemptions for the company.
The FTC expects the final executed terms to completely restore a competitive market structure in alignment with its longstanding settlement best practices.
USAP is on the clock. Comply, or face trial.
